Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation
暂无分享,去创建一个
V. Haufroid | P. Wallemacq | G. Schwartsmann | J. Biazus | D. D. Rosa | Vanessa De Oliveira | M. V. Antunes | R. Linden | S. Raymundo | Gustavo Gössling | J. A. Cavalheiro | Dilana E. Staudt | Tatiana Aparecida da Fontoura Timm | J. Biazús | Suziane Raymundo
[1] V. Haufroid,et al. CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. , 2015, Pharmacogenomics.
[2] V. Haufroid,et al. Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy. , 2015, Talanta.
[3] M. Hutz,et al. Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population , 2014, PloS one.
[4] L. Ekström,et al. Plasma Levels of 25‐Hydroxyvitamin D3 and In Vivo Markers of Cytochrome P450 3A Activity in Swedes and Koreans: Effects of a Genetic Polymorphism and Oral Contraceptives , 2014, Basic & clinical pharmacology & toxicology.
[5] J. Beijnen,et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen. , 2014, British journal of clinical pharmacology.
[6] G. Schwartsmann,et al. Development, validation and clinical application of a HPLC-FL method for CYP2D6 phenotyping in South Brazilian breast cancer patients. , 2014, Clinical biochemistry.
[7] S. Ahn,et al. Changes in serum hydroxyvitamin D levels of breast cancer patients during tamoxifen treatment or chemotherapy in premenopausal breast cancer patients. , 2014, European journal of cancer.
[8] R. Kim,et al. Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22 , 2014, Breast Cancer Research and Treatment.
[9] H. Tedesco-Silva,et al. CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients , 2013, Clinical pharmacology and therapeutics.
[10] E. Schuetz,et al. Interplay between vitamin D and the drug metabolizing enzyme CYP3A4 , 2013, The Journal of Steroid Biochemistry and Molecular Biology.
[11] R. Kim,et al. CYP3A4 and seasonal variation in vitamin D status in addition to CYP2D6 contribute to therapeutic endoxifen level during tamoxifen therapy , 2013, Breast Cancer Research and Treatment.
[12] V. Haufroid,et al. Endoxifen Levels and Its Association With CYP2D6 Genotype and Phenotype: Evaluation of a Southern Brazilian Population Under Tamoxifen Pharmacotherapy , 2012, Therapeutic drug monitoring.
[13] W. Sadee,et al. Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.
[14] C. Gordon,et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.
[15] T. Fehm,et al. Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma , 2011, Clinical pharmacology and therapeutics.
[16] J. Lindh,et al. Seasonal Variation in Blood Drug Concentrations and a Potential Relationship to Vitamin D , 2011, Drug Metabolism and Disposition.
[17] L. Natarajan,et al. Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes , 2011, Clinical pharmacology and therapeutics.
[18] F. Musshoff,et al. Pharmacogenetics and forensic toxicology. , 2010, Forensic science international.
[19] M. Beckmann,et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.
[20] H. Brauch,et al. Pharmacogenomics of tamoxifen therapy. , 2009, Clinical chemistry.
[21] M. Hutz,et al. Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians. , 2009, Pharmacogenomics.
[22] J. Brockmöller,et al. CYP2D6 und Tamoxifen: pharmakogenetische Neuentdeckung eines etablierten Medikaments? / CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug? , 2009 .
[23] S. Linn,et al. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. , 2009, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[24] A. Doehring,et al. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation? , 2009, PAIN®.
[25] A. Hofman,et al. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users , 2009, Breast Cancer Research and Treatment.
[26] Sara Gandini,et al. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. , 2007, Archives of internal medicine.
[27] R. Danesi,et al. CYP2D6 polymorphisms and the impact on tamoxifen therapy. , 2007, Journal of pharmaceutical sciences.
[28] Y. Böttiger. Use of omeprazole sulfone in a single plasma sample as a probe for CYP3A4 , 2006, European Journal of Clinical Pharmacology.
[29] David A. Flockhart,et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. , 2005, Journal of the National Cancer Institute.
[30] M. Rouini,et al. Simple chromatography method for simultaneous determination of dextromethorphan and its main metabolites in human plasma with fluorimetric detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[31] A. Peregrina,et al. CYP2C19‐ and CYP3A4‐Dependent Omeprazole Metabolism in West Mexicans , 2003, Journal of clinical pharmacology.
[32] A. Mirshahi,et al. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells , 2003, Hepatology.
[33] J. Bertino,et al. An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity , 2003, Clinical pharmacology and therapeutics.
[34] Hyeong-Seok Lim,et al. Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis. , 2014, Pharmacogenomics.
[35] V. Haufroid,et al. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. , 2013, Pharmacogenomics.
[36] L. Teh,et al. Pharmacogenomics of CYP2D6: molecular genetics, interethnic differences and clinical importance. , 2012, Drug metabolism and pharmacokinetics.
[37] L. Teh,et al. Pharmacogenomics of CYP 2 D 6 : Molecular Genetics , Interethnic Differences and Clinical Importance , 2012 .
[38] M. Meurer,et al. Vitamin D metabolism , 2010, Dermatologic therapy.
[39] A. A. Souto,et al. Simultaneous determination of omeprazole, hydroxyomeprazole and omeprazole sulphone in human plasma by isocratic HPLC-DAD: application to the phenotyping of CYP2C19 and CYP3A4 in brazilian volunteers , 2007 .